TA99 / Columbia University - LARVOL DELTA

[VIRTUAL] Enhancing the efficacy of antitumor antibodies with immune checkpoint inhibitors and targeted therapy in melanoma (AACR 2021) - "Here, using mouse preclinical models of melanoma (both solid tumor and lung metastasis), we found that the therapeutic efficacy of the specific antitumor antibody TA99 (anti-TYRP1) is significantly enhanced by immune checkpoint blockade...Our findings suggest that MEKi induced an increased expression of tumor-associated antigens, which, in combination with antitumor antibodies, generated a robust adaptive antitumor response that was sustained by immune checkpoint inhibition therapy. These improved therapeutic effects of specific antitumor antibodies by current standard-of-care therapeutics have potential near-term translation to the clinic, in light of fully humanized anti-TYRP1 antibodies currently in clinical development."

Checkpoint inhibition • Clinical • IO biomarker • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • HER2 Breast Cancer • Melanoma • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • BRAF • CD8 • FOXP3